3.00 USD
▼+0.10-0.33%
2026-08-03
市值
$342.14M
市盈率
—
EPS
-1.36
股息率
—
52 周区间
1.96 – 6.16
成交量
2.29M
Beta
1.80
目标价
12.93
52W 低 1.9652W 高 6.16
价格走势
公司简介
Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2...